News
-
Phase 3 MISSION Trial Of Nexavar (Sorafenib) In Patients With Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint Of Improving Overall Survival
5/22/2012
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that a Phase 3 trial evaluating Nexavar® (sorafenib) tablets in patients with advanced relapsed or refractory non-squamous non-small cell lung cancer (NSCLC) whose disease progressed after two or three previous treatments, did not meet its primary endpoint of improving overall survival.
-
InspireMD Announces Continued Progress In MASTER Trial
4/16/2012
InspireMD, Inc. (OTC BB: NSPR) (the "Company" or "InspireMD"), a medical device company focusing on the development and commercialization of its proprietary stent platform technology for use in patients with Acute Myocardial Infarctions, today announced that the 313th patient has been enrolled in the MASTER (MGuard™ for Acute ST Elevation Reperfusion) trial. The trial is scheduled to enroll 432 patients in total and the Company is on track to release preliminary top line results in the third quarter of 2012
-
Quintiles To Quantify Healthcare Decisions
4/2/2012
Quintiles and Archimedes Inc. recently announced an agreement to co-promote clinical and commercial solutions for biopharmaceutical companies to help reduce the time and expense associated with developing and marketing novel therapies.
-
Abbott Initiates Clinical Trial To Study Drug Eluting Bioresorbable Therapy For Treatment Of Peripheral Artery Disease
12/28/2011
Abbott recently announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in Europe evaluating the safety and performance of the novel Esprit drug eluting bioresorbable vascular scaffold (BVS) for the treatment of blockages in the superficial femoral arteries (SFA) and iliac arteries that have resulted in claudication (leg pain upon walking).
-
CorMatrix Receives Full IDE Approval For The Prospective, Randomized Evaluation Of New Onset Postoperative Atrial Fibrillation In Patients Receiving The CorMatrix® ECM® For Pericardial Closure
11/21/2011
CorMatrix Cardiovascular, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted the company full IDE approval for its ongoing multi-center, prospective, randomized clinical trial aiming to demonstrate the safety and efficacy of the CorMatrix ECM for Pericardial Closure to reduce the incidence of new onset postoperative atrial fibrillation following isolated primary coronary artery bypass graft (CABG) surgery
-
INC Research, SAS Collaborate To Improve Clinical Trials Outcomes
11/17/2011
INC Research, a therapeutically focused clinical research organization (CRO) with a Trusted Process for delivering reliable results, and SAS are working together to improve clinical development risk management and achieve targeted product profiles through analytics.
-
The Cardiovascular Research Foundation And The Angiographic Core Laboratory Of Harvard Medical Faculty Physicians At Beth Israel Deaconess Medical Center, Inc. Announce CRFiCOR, A Collaborative Alliance To Enhance Patient Care
11/8/2011
The Angiographic and Imaging Core Laboratories of the Clinical Trials Center (CTC) at the Cardiovascular Research Foundation (CRF) in New York have formed a collaborative alliance with the Angiographic Core Laboratory of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center, Inc. (HFMP).
-
Lilly Steps Up Efforts To Improve Diversity In Clinical Trials
9/26/2011
Racial and ethnic minorities are more likely to develop cancer and die from it than the general U.S. population.
-
NORD And DIA To Host Conference On Rare Diseases And Orphan Products
9/19/2011
The National Organization for Rare Disorders (NORD) and the Drug Information Association (DIA) will host the U.S. Conference on Rare Diseases and Orphan Products in Washington, D.C. October 11-13. Everyone with an interest in rare diseases or orphan products is invited.
-
FDA Seeks Comment On Proposed Guidelines For High-Quality Clinical Studies
8/19/2011
The FDA recently issued draft guidance to help researchers and manufacturers design better quality clinical studies in support of premarket approval (PMA) applications for medical devices.